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NEW TOPICAL OPHTHALMIC PHARMACEUTICALS 
-AN UPDATE 
This review is designed to inform primary care 
practitioners about new topical ophthalmic drugs that have 
demonstrated effectiveness in the treatment of these commonly 
encountered conditions: vernal keratocon junct i vi tis; acute 
allergic conjunctivitis; bacterial conjunctivitis, and 
corneal ulcers. Recent investigation has revealed three 
effective treatments for vernal keratoconjunctivitis 
including lodoxamide tromethamine, cyclosporine, and 
suprofen. Effective treatment opt ions for acute allergic 
conjunctivitis are demonstrated by ophthalmic flurbiprofen, 
ketorolac tromethamine, levocabastine, and nedocromil sodium. 
Treatments for bacterial conjunctivitis include ophthalmic 
t r imethopr im-polymixin B, norf loxacin, ciprof loxacin, and 
ofloxacin. Ophthalmic ciprofloxacin is also used for the 
treatment of corneal ulcers. 
VERNAL KERATOCONJUNCTIVITIS 
Vernal keratoconjuctivitis is an often severe, non-
infectious, allergic disease that is usually seen in children 
and young adults. It predominately affects young males and 
occurs more frequently in warm climates. The disease causes 
papillary hypertrophy of the superior tarsal conjunctiva that 
results in a cobblestone appearance.. Limbal papillae may 
form and extend onto the cornea and result in pannus. 
Punctate epithelial keratopathy and epithelial erosions are 
often seen, and in severe cases, vision loss occurs due to 
corneal ulcers. The clinical signs of this disease include 
intense photophobia, tearing, conjunct i va l hyperemia, 
injection and stringy mucus discharge. Patients complain of 
severe itching that is characterized by seasonal, 
intermittant exacerbations. The disease is self-limiting and 
generally lasts from four to six years; however, in middle-
aged patients the disease may not resolve and can cause 
severe ocular complications. 
Conservative management i s effective in mild cases, but 
the treatment of vernal conjunctivitis in severe cases is 
challenging. Topica l and sub-conjuntival corticosteroids 
remain the most effective treatment for alleviating the 
symptoms of vernal keratoconjuctivitis b u t long-term use can 
result in vision loss by cataract formation and glaucoma in 
some patients. 
Cromolyn sodium has shown great promise as a safe 
substitute for prednisolone acetate. It acts as an anti-
allergy agent by stab i lizing the mast ce l l and inhibiting 
activation of eosinophils and neutrophils. Since the removal 
of this commercially available solution, the sea r ch for safe 
and effective treatment of verna l conj unctivitis has rece i ved 
added emphasis. 
Lodoxamide Tromethamine 
Lodoxamide tromethamine was originally developed for the 
prophylaxis of mast cell mediated allergic disease. This 
mast cell stabilizer is used as a nonbronchodilator for 
asthma treatment. In a multi-center c l inical study, 
lodoxamide 0.1% ophthalmic solution was found to be more 
effective than topically applied 2% Opticrom for alleviating 
the signs and symptoms in various types of ocular allergy 1 . 
The efficacy and safety of lodoxamide 0.1% ophthalmic 
solution was compared with cromolyn sodium 4 9o in a recent 
study 2 • The clinical efficacy of lodoxamide 0. Po was 
statistically superior (p<.05) to cromolyn sodium 4% in 
alleviating four of the primary symptoms associated with 
vernal keratoconjuctivitis (itching, tearing, foreign-body 
sensation, and discomfort) and five of the primary clinical 
signs (Tranta' s dots, palpebral conjuctival changes, bulbar 
conjunctival hyperemia, erythema of the eyelids and 
periorbital tissues, and epithelial disease) At no time 
during the study was the 4% cromolyn sodium superior to the 
0.1% lodoxamide ophthalmic solution. Adverse reactions from 
both treatments were infrequent and not serious. Two of the 
sixty patients treated with lodoxamide solution were 
discontinued from the study due to discomfort and nausea, and 
one of the sixty patients treated with the cromolyn sodium 
solution was discontinued from the study due to erythema and 
chemosis. Both treatment regimens in this study were shown 
to be safe and well tolerated for topical use when one drop 
four times daily was instilled for up to 28 days. Ophthalmic 
0.1% lodoxamide is available in Europe in a commercial form 
called Alomide3. It is used for the treatment of vernal 
keratoconjunctivitis, atopic kerato-conjunctivitis and giant 
papillary conjunctivitis. Recently, it has been submitted by 
Alcon Laboratories for FDA approval. 
Cyclosporine 
Another drug currently under study for topical 
ophthalmic use is cyclosporine. As an immunomodulator, it 
is already used in its oral form for the treatment of ocular 
inflammatory conditions including corticosteroid-resistant, 
sight-threatening, endogenous uveitis, and corneal graft 
rejection. In an animal study, treatment with cyclosporine 
by oral, intraperitoneal, or intravenous routes resulted in 
high levels of the drug in the liver and spleen, but did not 
show any significant accumulat ion of the drug in the eye, 
except for the animals treated intravenously 4 where 
cyclosporine was detected in the chorioretinal complex. 
Topical application of cyclosporine 2 % suspended in an 
oil vehicle, resulted in a high concentration of the drug in 
the conjunctiva and cornea only. Intraocular penetration was 
not observed and topical application of the drug did not 
induce any significant systemic accumulation. When 
cyclosporine was suspended in alcohol there was intraocular 
penetration, but this was due to induced damage of the 
corneal epithelium by the alcohol. Only trace amounts of 
the drug were detected in the blood, liver or spleen. While 
the topical form is currently unavailable in the U.S., there 
have been s eve ral clinical studies conducted in the Middle 
East. 
In a study conducted by Ben Ezra at the Pediatric 
Ophthalmology Unit in Hadassah University Hospital, 
Jeruselum, twelve children with severe, bilateral vernal 
keratoconjuctivitis were treated with topical cyclosporine 5 . 
The children had at least a two year history of the 
affliction and previously r e quired systemic corticosteroid 
treatment because topical corticosteroids and 2% cromolyn 
preparations were not effective. Nine patients markedly 
improved after the six week treatment period and six of these 
patients showed no signs of disease by slit-lamp observation. 
Although subjective improvement was lacking in only one case, 
three patients remained free of symptoms two months after 
cessation of the topical 2% cyclosporine treatment. The only 
side effect encountered was maceration of the skin at the 
lateral canthus that was present after six days of treatment. 
It healed during the second week after excess medication was 
removed more thoroughly after each application. 
The effects of topica l 2% cyclosporine were evaluated in 
a clinical trial conducted at King Saud College of Medicine 
and El Maghraby Eye Hospital, Saudi Arabia 6 • The results 
indicated a significant decrease (p<.OS) in the conjunctival 
hyperemia, punctate keratitis, and Tranta's dots in a group 
treated with cyclosporine. The number and size of giant 
papillae were not influenced by the topical cyclosporine but 
the treatment showed a marked decrease (p<.01) in phbtophobia 
which was most likely due to the reduction of punctate 
keratitis. Neither adverse e ffects nor detectable blood 
levels of cyclosporine were found and the liver and kidney 
function tests were the same before and after treatment. The 
intraocular pressure was measured before, during and after 
treatment and no statist i cally significant difference was 
found. This study concluded that the topical administ ration 
of 2% cyclosporine was found to be a safe and effective 
short-term therapy for vernal keratoconjunctivitis. 
Suprofen 
Suprofen, a nonsteroidal anti-inflammatory agent has 
recently become commercially available as a topical 
ophthalmic 1% solution called Profenal. It is indicated for 
the inhibition of intraoperative miosis but has also been 
shown effective in the treatment of vernal 
keratoconjunctivitis. 
Topical ophthalmic 1% suprofen applied 4 times daily for 
21 or 28 days reduced signs of papillae and discharge in a 
multi-center study 7 . Results indicated that itching, foreign 
body sensation, mucous strands, and discomfort were relieved 
after only seven days of treatment and adverse drug reactions 
were not experienced . 
Profenal ophthalmic solution has been shown to have no 
significant effect on i ntraocula r pressure. As with many 
anti-inflammatory agents, Profenal is contraindicated in 
patients with active herpes simplex keratitis. Although use 
of oral suprofen has been associated with a syndrome of acute 
flank pain and generally reversible renal insuffiency that 
occurs in approximately 1 ·in 3500 patients, there is no 
evidence that it results from topical ocular use. 
ACUTE ALLERGIC CONJUCTIVITIS 
Flurbiprofen 
Flurbiprofen sodium is a non-steroida l anti-inflammatory 
agent that has recently become commercially available as a 
topical ophthalmic 0. 03% solution called Ocufen. It is 
indicated for inhibition of intraoperative miosis but has 
been evaluated in the treatment of antigen-induced allergic 
conjunctivitis 8 • The results showed that eyes treated with 
the 0. 03% flurbiprofen sodium solution had significantly 
(p<.OS) less conjunctival, ciliary, and episcleral hyperemia, 
and ocular itching than eyes treated with the vehicle alone. 
Levocabastine 
Levocabastine, a highly potent and specific histamine H1 
receptor antagonist, is another new drug under investigation 
for use in the treatment of seasonal allergic conjunctivitis. 
Sixty-five subjects were administered increasing amounts of 
allergen (ragweed,cat, or grass) until a 2+ score of itching 
and redness was obtained 9 • The subjects were allowed to 
remain in the study only if they developed a 2 + score of 
itching and redness from a second exposure to the allergen. 
After ophthalmic levocabastine was instilled in one eye and 
placebo in the other, the subjects were again exposed to the 
allergen. Signs and symptoms were graded at 3, 5 and 10 
minute intervals after exposure. The results of this study 
showed that topical ophthalmic levocabastine dramatically 
decreased itching, tearing, hyperemia, chemosis and lid 
swelling (p<.001) initially and after a 4 hour time interval. 
Azevedo compared topi cal ophthalmic 0.5 mg/ml 
levocabastine with topical 20 mg/ml sodium cromoglycate and a 
placebo in a 4 week double-blind trial involving 64 patients 
with seasonal a l lergic conjunctivitis 10 • Eye irritation 
following instillation of levocabastine was the most frequent 
complaint, however, this was fewer than the number of 
patients who 
sodium-treated 
frequently in 
experienced eye irritation in the cromolyn 
group. Patients were asymptomat ic more 
th e levocabastine group (53%) than the 
cromoglycate (31 %, p=0.02) or placebo (34%, p=0.08) groups, 
and experienced a statistically significant (p<. 05) lower 
degree of symptoms than the cromoglyca te (p=O. 03) and the 
placebo-treated patients (p=O. 007) . The differences between 
the levocabastine-treated group and the cromoglycate-treated 
group were most apparent at the beginning of treatment where 
levocabastine provided faster relief of symptoms. 
In a multi-center study conducted in Sweden, sixty-four 
pat i ents were confirmed to have seasonal allergic 
conjunctivitis by positive skin prick tests before undergoing 
random treatment with levocabastine or sodium cromoglycate 
eyedrops. The results demonstrated that application of 
levocabastine eyedrops twice daily was as effective (p<. 05) 
as sodium cromoglycate applied four times da ily for 
decreasing symptoms of itching, redness and lacrimation 11 . 
In a study of twenty-one clinical trials reported by 
Janssens and Busche involving 1218 patients with allergic 
conjunctivitis, levocabastine eyedrops were found to provide 
symptomatic relief similar to cromoglycate and significantly 
better relief (p<. 05) than placebo12 . Levocabastine had a 
fast onset of action, with 94% of patients experiencing 
symptom relief within 15 minutes of the first application of 
the eyedrops. 
In one of these clinical tria 1 s, the ini t ia 1 ocular 
irritation of levocabastine was compared to that of 
antazoline/naphazoline. Ocular irritation was experienced in 
forty-four percent of the sixty-nine patients in the 
antazoline/naphazoline group. No ocular irritation was 
experienced in the levocabastine group. 
Levocabastine is available in Europe as a topical 
ophthalmic product called Livostin and is used for treatment 
of acute allergic conjuctivit is. It appears to be a 
promising ophthalmic antiallergy agent for fast relief in 
patients with existing symptoms of acute allergic 
conjunctivitis. It has no t yet been approved for ophthalmic 
use in the United States but has been submitted to the FDA 
for approval. 
Nedocromil sodium 
Nedocromil sodium, a relatively new compound that has 
mast cell stabilizing and anti-inflammatory properties, has 
been evaluated for its efficacy in treating seasonal allergic 
conjunctivitis . Its action is much like cromolyn sodium. 
Tilavist is a 2% nedocromil sodium topical ophthalmic 
agent commercially available in Finland. In a multicenter 
double-blind study involving 126 allergy patients, one drop 
of 2% nedocromil sodium instilled twice daily was compared to 
placebo eye drops 1 3 . A statistically significant (p<. 0 5) 
decrease in excess lacrimation was shown in the nedocromil 
treated patients. Although patients used concomitant anti-
allergy treatment which l eft little room for improvement of 
symptoms, the final opinions of both clinicians and patients 
were significantly (p<.01) in favor of nedocromil sodium 
versus placebo. 
In another investigation involving 64 patients over a 
four week trial period, ophthalmic 2% nedocromil sodium was 
applied twice daily and compared to placebo eye drops 14 . The 
results showed statistically significant improvement (p<.05) 
of symptoms during periods of high pollen count using 
nedocromil sodium. 
In a clinica l trial conducted by four University 
Hospitals in the U.S., 140 patients who had a history of 
seasonal allergic conjunctivitis requiring continuous 
treatment during the two previous pollen seasons and a skin-
test reaction to ragweed of at least 2+ were selected15 . They 
were randomly assigned to a placebo-treatment group or a 
topical ophthalmic 2% nedocromil sodium-treatment group for 
eight weeks. Concomitant medications were not allowed for the 
treatment of ocular allergy during that period. Results 
showed that during the peak ragweed pollen season, patients 
using 2% nedocromil sodium had statistically significant 
reductions in conjunctival injection (p< .001) and overall 
disease severity(p<.001) when compared to the placebo-treated 
group. Symptoms of tearing and conjunctival edema were lower 
in the 2% nedocromil-treated patients but not enough to be 
statistically significant. Transient eye burning was 
experienced by 12% of the nedocromil-treated patients and 7% 
of the placebo-treated patients. Ocular stinging was reported 
by another 10% of the nedocromil-treated group and 3% of the 
placebo-treated group. An unpleasant taste was experienced 
by 13% of the nedocromil-treated group. 
These studies indicate that topical ophthalmic 2% 
nedocromil sodium applied twice daily is safe and efficacious 
for treating seasonal allergic conjunctivitis. It is not 
available as an ophthalmic product in the United States and 
has not been submitted to the FDA for approval yet. 
Ketorolac tromethamine 
Allergan Pharmaceuticals received FDA approval in 
November, 1992 for a topical ophthalmic 0. 5% ketorolac 
tromethamine solution called Acular. It became commercially 
available in February, 1993. Ophthalmic ketorolac is a 
nonsteroidal anti-inflammatory agent that has been marketed 
as a treatment for seasonal acute allergic conjunctivitis.' 
Published clinical studies are not avai lable at this time. 
BACTERIAL CONJUNCTIVITIS 
Ocular surface bacterial infections are a frequently 
encountered clinical problem. The most common causes of 
bacterial blepharitis and conjunctivitis include 
Staphylococcus aureus, Staphylococcus epidermidis, 
Streptococcus pneumoniae and Haemophilus influenzae. Less 
frequent causes of bacterial infections include Neisse ria 
gonorrhoeae, Pseudomonas aeruginosa and Moraxella. Treatment 
for mild bacterial conjunctivitis is often initiated before 
the causative agent is identified, so a wide spectrum anti-
bacterial drug is very important. Several new topical agents 
have been introduced that have this wide spectrum of action. 
Tromethoprim-polymyxin B 
Polytrim ophthalmic solution contains trimethoprim and 
polymyxin B. Polymyxin B is known for its effect iveness 
against gram negative pathoge ns including Pseudomonas 
aeruginosa. Trimethoprim is active against most common gram 
negative and gram positive pathogens including Staphylococcus 
aureus, Staphylococcus epidermidis, Streptococcus pneumoniaea 
and Haemophilus influenzae. For mild to moderate infections, 
the recommended dosage is one drop in the affected eye every 
three hours for a period of 7 to 10 days. 
In four randomized, double-blind studies, four hundred 
and forty-eight patients with bacterial conjunctivitis were 
evaluated after treatment with trimethoprim-polymyxin B 
sulphate or chloramphenicol ophthalmic ointments 16 • The 
patients were treated four times a day for seven days in 
three groups and three times a day for five days in one 
group. The results indicated no statistically significant 
differences between treatment regimens. Both treatments 
were effective. 
The study reported by Lorh showed no statistically 
significant differences when comparing the efficacy of 
trimethoprim-polymixin B (Polytrim) to gentamicin sulfate 
(Garamycin} and sodium sulfacetamide (Sodium Sulamyd) 
ophthalmic solutions for treatment of conjunctivitis caused 
by Haemophilus influenzae and Streptococcus pneumoniae 17 • 
Trimethoprim-polymixin B appeared to eradicate Haemophilus 
influenzae faster than the gentamicin sulfate or the sodium 
sulfacetamide solutions but clinical significance was not 
established. 
The efficacy of trimethoprim-polymixin B ophthalmic 
solution was compared to neomycin - polymyxin B-gramicidin and 
chloramphenicol utilizing 230 patients with bacterial 
conjunctivitis 18 • Most of the bacteria cultured from the pre-
treatment swabs included H. influenzae, Staphylococcus aureus 
and Streptococcus pneumoniae. Gibson reported no 
statistically significant differences between trimethoprim-
polymixin B and neomycin-polymyxin B-gramicidin but 
trimethopr im-polymyxin B was found to be significantly 
superior (p= 0.03) to chloramphenico l in treat ing bacterial 
conjuctivitis. These patients had no history of allergic 
hypersensitivity to any of these drugs and adverse effects 
were minimal. The results of a similar study showed no 
statistically significant differences in e ff ectiveness when 
trimethoprim-po lymyxin B ophtha lmic solution was compared to 
neomycin-polymyxin B-gramicidin ophthalmic solution for 
treatment of bacterial conjunctivitis in 48 patients19 . 
Lamberts demonstrated that a statistically significant 
difference could not be established between treatments of 
tr imethoprim-sulfacetamide-polymyxin B ophthalmic solution 
and polymyxin B-neomycin-gramicidin ophthalmic solution for 
treatment of bacterial conjunctivitis 20 • The trimethoprim-
sulfacetamide-polymyxin B combination was also compared to 
an ophthalmic solution containing trimethoprim-polymyxin B to 
evaluate the contribution of the sulfacetamide component. 
The results indicated that the sulfacetamide component was 
unnecessary. 
These clinical trials indicate Polytrim is an effective 
alternative to conventional treatment of bacterial 
conjunctivitis. It is especially useful in patients where 
contact 
neomycin 
allergic hypersensitivity to 
or sulfonamide has occurred as 
chloramphenical, 
hypersensitivity 
reactions to Polytrim have been rare. 
Norfloxacin 
The flouroquinolones also represent a class of 
antibacterials that have a wide spectrum of action. Three 
flouroquinolones are currently under study for ophthalmic 
use. Clinical studies indicate they are as effective as 
conventional treatment options for ocular bacterial 
infections. Resistance to these drugs is currently not a 
problem making ophthalmic flouroquinolones valuable when 
aminoglycoside-resistant organisms are responsible for 
ophthalmic bacterial infections. 
Chibroxin by Merck Sharp & Dohme is a topical ophthalmic 
0.3% norfloxacin solution that has recently become 
commercially available. This fluoroquinolone is a synthetic 
broad-spectrum anti-bacterial agent indicated for treatment 
of bacterial conjuctivitis. The recommended dose is one or 
two drops in the affected eye four times daily fo r up to 
seven days. Depending on the severity of the infection, the 
dosage may be one or two drops every two hours during waking 
hours. 
The in vitro activity of norfloxacin was compared to ten 
other anti-microbial agents against bacteria in 17 genera21 . 
Gram positive bacteria, including Staphylococcus aureus, and 
its methicillin-resistant strains were very susceptible to 
norfloxacin. Streptococcus pneumoniae and other streptococci 
were relatively less susceptible to norfloxacin. Norfloxacin 
was the most effective agent against the gram negative 
organisms including Klebsiella, Enterobact e r, Moeganella, 
Proteus, Serratia and Haemophilus. Gentamycin was only half 
as active as norfloxacin against Pseudomonas aeruginosa. 
Other in vitro studies showed norfloxacin to be effective 
against Chlamydia trachomat is22 and Neisseria gonorrhoeae2 3 . 
A recent 1992 report indicated ophthalmic norfloxacin 
was clinically similar to ophthalmic gentamicin when two-
hundred forty-five patients were treated with ophthalmic 0.3% 
norfloxacin and two-hundred forty three patients were 
treated with ophthalmic 0.3% gentamicin for one week 2 4 . The 
most prevalent gram negative bacteria in this study included 
Enterobacteriaceae (species of Escherichia, Klebsiella, 
Enterobacter, Serratia, and Proteus), Haemophilus influenzae 
and Moraxella species. The most prevalent gram positive 
bacteria included Staphylococcus aureus, Staph epidermidis, 
Micrococcus species, a-hemolytic Streptococcus, and 
Streptococcus pneumoniae. 
Jacobson found that the safety and efficacy of 
ophthalmic 0.3 % norfloxacin and ophthalmic 0.3% tobramycin 
were similiar for treatment of bacterial conjuctivitis25, 
One-hundred twenty patients were randomly assigned to the two 
treatment groups and were included in the study only if they 
exhibited conjunctival hyperemia and at least one of the 
following: purulent or mucopurulent exudate, crusting on the 
eyelids, thickened red lid margins, and loss of cilia. 
Treatment included one drop in the affected eye every 2 hours 
while awake on the first day and four times daily for the 
rest of the week. Haemophilus influenzae was the most 
prevalent bacteria in this study. Streptococcus pneumoniae 
and Staphylococcus aureus were also isolated from conjuctival 
swabs. Adverse effects included two cases of inflammation 
and one case of ocular stinging in the norfloxacin group and 
three cases of corneal stippling in the tobramycin-treated 
group. 
Ofloxacin 
Ofloxacin, also a flouroquinolone, has been submitted to 
the FDA by Allergan for approval as an ophthalmic solution 
called Ocuflox. Published studies on ophthalmic ofloxa~in 
are limited but a recent study indicated maximum serum 
ofloxacin concentrations after 10 1/2 days of topical dosing 
were more than 1000 times lower than those reported after 
standard oral doses of 300 mg ofloxacin26 • It is unknown 
when this broad spectrum antibacterial will become 
commercially available. 
CORNEAL ULCER 
Ciprofloxacin 
Ciprof l oxacin is another flouroquinol one that has been 
recently approved for ophthalmic use. This synthetic broad-
spectrum anti-bacterial agent is commercially available in a 
0. 3% topical ophthalmic solution called Ciloxan. It is 
recommended for treatment of bacterial corneal ulcers and 
conjunctivitis. Published studies about this ophthalmic 
solution are limited, however a recent study compared 
ophthalmic ciprofloxacin with cefazolin and fortified 
gentamicin sulphate solutions in the treatment of ulcerative 
kerat itis 27 • The most common organisms isolated were 
Staphylococcus epiderm idis (approximately 33%), 
Staphylococcus aureus (approximately 15%) and Pseudomonas 
aeruginosa (approximately 1 7%) • The duration of antibiotic 
treatment was significantly shorter in the ciprofloxacin-
treated group. Ophthalmic ciprofloxacin treatment was 27+/-
15 days compared to 89+/- 117 days of cefazolin and fortified 
gentamicin sulphate treatment. Both treatments were 
effective and no statistically significant difference was 
found. 
Of 
received 
the drugs mentioned in 
FDA approval and are 
this review, many have 
commercially available at 
present. The studies indicate these topical ophthalmic 
agents are a reasonable addition to the list of effective 
treatments already available. 
Ophthalmic Topical Agents 
VERNAL KERATOCONJUCTIVITIS: APPROVED by FDA NOT APPPROVED by FDA 
Lodoxamide tromethamine X 
Cyclosporine X 
Suprofen X 
ACUTE ALLERGIC CONJUCTIVITIS: 
------
Flu rbiprofe n X 
Levocabastine X 
Nedocromil sodium X 
Ketorolac tromethamine X 
BACTERIAL CONJUCTIVITIS: 
Tromethoprim-polymyxin B X 
Norfloxacin X 
Ofloxacin X 
CORNEAL ULCER: 
Ciprofloxacin X 
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